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Abstract
Background: Mesothelin is a membrane-bound glycoprotein. Although the biologic function of mesothelin is not
very clear, researchers have found that it plays a role in the survival, proliferation, and migration of tumor cells.
Identified as a tumor-associated biomarker, mesothelin is more often overexpressed in triple-negative breast cancer
(TNBC) than in common luminal breast tumor subtype or normal tissues. The objective of this review is to
determine the association between the expression of mesothelin and overall survival in patients with TNBC.
Methods/design: We will search the following electronic databases: MEDLINE, EMBASE, the Cochrane Central
Register of Controlled Trials (CENTRAL), PubMed, and Web of Science with no time or language restriction.
Prospective or retrospective longitudinal studies that investigate mesothelin expression in TNBC or the prognosis of
TNBC with mesothelin baseline measurement will be selected. Two reviewers will independently assess every
abstract or full text for inclusion. Data on clinical outcomes, as well as on study design, research setting, study
population, demographic characteristics of the participants, and methodological quality, will be extracted using a
structured codebook developed by the authors. A pooled measure of associations will be assessed through
meta-analyses if appropriate. Heterogeneity across the included studies will be evaluated using the I2 statistics.
Findings will be reported according to the Meta-Analysis of Observational Studies in Epidemiology (MOOSE)
guidelines and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. The
quality of evidence and risk of bias of the studies will be evaluated.
Discussion: The aim of this systematic review is to synthesize the evidence regarding the association between the
expression of mesothelin and the survival outcomes of patients with TNBC. A better understanding of the expression
frequency and prognostic value of mesothelin in TNBC will be essential to identifying a novel therapeutic target.
Systematic review registration: PROSPERO CRD42016036212
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Background
Description of the condition
Triple-negative breast cancer (TNBC), which is character-
ized by a lack of expression of estrogen receptor (ER), pro-
gesterone receptor (PR), and human epidermal growth
factor receptor 2 (HER2), is an aggressive subtype of breast
neoplasms. About 15 % of breast cancers are TNBC [1],
and they tend to be more common in younger women [2].
TNBC has a relatively higher rate of relapse and worse
overall survival rate than other forms of breast cancer [3].
Description of the prognostic factor
Mesothelin is a membrane-bound glycoprotein. Its ex-
pression is limited to mesothelial cells and some malig-
nant neoplasms [4]. The biological function of mesothelin
is not very clear. However, researchers have found that it
has a role in the survival, proliferation, and migration of
tumor cells [5].
How the prognostic factor may be related to health
outcomes
Mesothelin is identified as a biomarker for TNBC be-
cause it is overexpressed in TNBC while its expression is
limited in the common luminal breast tumor subtype
and normal tissues [6]. As such, it is hypothesized that
the expression of mesothelin in TNBC is of relevance
for patients’ outcome.
Although TNBC is more sensitive to chemotherapy
than other types of breast cancer, cytotoxic agents often
result in numerous adverse side effects. Targeted ther-
apies on specifically overexpressed antigens have been
successful in the treatment of some malignant diseases
[7]. TNBC lacks effective targeted therapies that can
improve its chemotherapy. Mesothelin is a potential
candidate for targeted therapies for TNBC because of
its overexpression in TNBC cells and limited expression
in normal tissues. Therefore, a better understanding of
the expression levels of mesothelin and its prognostic
value in TNBC may provide evidence necessitating the
role of mesothelin as a therapeutic target, thus leading
the path of improving health outcomes of patients with
TNBC.
Why it is important to do this review
Li et al. and Tozbikian et al. showed that the levels of
mesothelin expression in TNBC were an independent
prognostic marker that correlates with low survival rates
[8, 9]. However, two other studies failed to demonstrate
such an association between the presence of mesothelin
and poor clinical outcome [10, 11]. These controversial
results may result from insufficient samples and different
study designs. To the best of our knowledge, no system-
atic review or meta-analysis has ever been done on this
topic. The present systematic review aims to evaluate
the frequency of mesothelin expression and the value of
mesothelin as a prognostic marker for TNBC.
Objectives
The primary objective of this review is to synthesize
available evidence on the association between the ex-
pression of mesothelin and overall survival of patients
with TNBC. The secondary objectives include determin-
ing the association between the expression of mesothelin
and disease-free survival (DFS), relapse-free survival
(RFS), distant metastases, and mortality and, where feas-
ible, combining the results of original studies using
meta-analysis and critically evaluating the literature and
identifying future research needs.
Methods
Study registration
This project has been registered with the international
prospective register of systematic reviews (PROSPERO)
as number CRD42016036212. This systematic review
protocol has been designed and reported using Preferred
Reporting Items for Systematic Review and Meta-
Analysis Protocols (PRISMA-P) 2015 statement [12] and
the Meta-Analysis of Observational Studies in Epidemi-
ology (MOOSE) guidelines [13]. The PRISMA-P check-
list has been used in the preparation of this protocol and
is included as an additional file (see Additional file 1).
Eligibility criteria
Types of study designs
We will include both prospective and retrospective lon-
gitudinal studies in this systematic review. The studies
will be eligible if they evaluated mesothelin expression in
TNBC or the prognosis of TNBC with mesothelin at
baseline measurement. We will consider both explora-
tory and confirmatory prognostic factor investigation
studies. When overlapping data of the same patient
population are included in more than one publication,
only the most recent or complete study will be used in
the meta-analysis.
Types of participants and setting
Studies would be included in this systematic review if
the participants had TNBC. No age, intervention, or set-
ting restrictions will be placed.
Exposure variable
For the prognostic studies, our main exposure will be
mesothelin expression measured by immunohistochemi-
cal analysis.
Types of outcome measures
Our primary outcome will be overall survival (OS). If
the OS is not reported in the study, we will collect its
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relevant surrogate outcomes, which include DFS or RFS,
distant metastases, and mortality.
Time frame
The prognostic studies should be at least 1-year duration
for follow-up. We will group outcome data into three
time periods for analysis purposes: short-term (≤3 years),
medium-term (3–5 years), and long-term follow-up
(≥5 years).
Hypothesis
The research hypothesis of this systematic review is that
the expression of mesothelin in patients with TNBC is
associated with poor health outcomes.
Primary outcome
The primary outcome of interest is the OS in
patients with mesothelin-positive TNBC, which were
estimated from the date of surgery to the date of the
final follow-up visit, or the date of the end of the
study, or the date of death.
Secondary outcomes
DFS and RFS—time-to-event data which were
measured from the date of surgery to the date of the
first documented local or distant recurrence. Patients
who died or lost to follow-up before experiencing the
relevant events were considered censored at their
dates of the last follow-up.
Distant metastases—estimated by subsequent distant
metastases, interval to metastases.
Mortality—measured by mortality rate.
Search methods for identification of studies
Electronic searches
A comprehensive literature search will be done for ori-
ginal articles analyzing the expression and prognostic
value of mesothelin in TNBC. The electronic database
sources we will search are MEDLINE, EMBASE, the
Cochrane Central Register of Controlled Trials (CEN-
TRAL), PubMed, and Web of Science with no restric-
tions on time and languages. As there may be limited
published research on mesothelin in TNBC, we will
increase our search sensitivity by finding any articles
related to TNBC and mesothelin. The search terms will
be “triple negative breast cancer,” “triple negative breast
carcinoma,” “triple negative breast neoplasm,” “TNBC,”
and “mesothelin.”
A three-step search strategy will be utilized in this re-
view. First, we will explore database subject headings
and text words. An initial pilot search in MEDLINE will
be undertaken followed by analysis of the text words
contained in the title and abstract and of the subject
headings used to describe the article. Second, we will
search using all identified keywords and index terms
across all included databases. And finally, the reference
list of all identified reports and articles will be searched
for additional studies. Studies published in all languages
will be considered for inclusion in this review. Please
refer to Additional file 2 for the full search strategy and
Additional file 3 for the primary literature screening
form we will use during this stage.
Searching other resources
We will search for additional references by cross-
checking bibliographies of retrieved studies or relevant
reviews. We will also contact researchers in the field to
identify additional trials that may have been eligible for
inclusion. Mediconf (http://www.mediconf.com/) will be
used to search conference abstracts.
Data collection and analysis
Selection of studies
Our selection of studies will follow the four-phase flow
diagram (Additional file 4) referring to the PRISMA
statement. The literature search results will be uploaded
to EndNote X7 Software, which will facilitate the collabor-
ation among reviewers during the study selection process.
The screening will be conducted using a pretested
screening form. Titles and abstracts will first be screened
for relevance and presence of the eligible criteria listed
above (the second phase). Full-text articles for potentially
eligible titles or abstracts will be downloaded for further
assessment. Articles will be classified as (1) included, (2)
excluded, or (3) uncertain. For each phase of screening,
the kappa statistic will be performed to calculate inter-
rater agreement. Two authors (MW and AL) will inde-
pendently perform the filtering of the selected pieces of
literature. Disagreements will be resolved by consensus or
by contacting a third author when consensus cannot be
reached (LM or LT).
Data extraction and management
Data will be collected using a predesigned data col-
lection form which will be pilot tested beforehand
(Additional file 5). The following details will be extracted:
study characteristics (such as the first author, the country,
the year of publication, the study design, and the sample
size); participants’ characteristics (the age, the stage of
breast cancer, and the interventions); study exposure
(the technique used to quantify mesothelin, the cut-off
to determine mesothelin positivity, and the number of
mesothelin positivity and controls); and outcome vari-
ables (median OS, median disease-free survival (DFS)
or relapse-free survival (RFS), number of distant metas-
tases, number of deaths, and 95 % confidence intervals,
as well as events rates and numbers at risk during
short-term (≤3 years), medium-term (3–5 years), and
long-term follow-up (>5 years more) intervals). If a
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study has insufficient details to extract the number of
events, hazard ratio (95 % CI) or odds ratio (95 % CI),
but provides the survival curves, we will use the sur-
vival curve approach to extract required data to obtain
estimates of association [15].
If necessary, modifications will be done to the data col-
lection form after testing the reliability of data abstraction
on a random sample. The review authors (WM and AL)
will independently extract the data, resolve discrepancies
by discussion, or refer to the third reviewer (LM or LT).
Breast carcinoma was defined as TNBC when nuclear
staining is <1 % for both ER and PR, and membranous
staining is <10 % of HER2 on immunohistochemistry
(IHC) staining or negative gene amplification was found
by fluorescence in situ hybridization (FISH) [16, 17].
Generally, an H-score is used to quantify the mesothelin
staining. H-score (final score ranging between 0 and
300) is the combination of the percentage of tumor
cells with positive staining (0–100 %) and the inten-
sity of staining (1+, 2+, and 3+) [18]. We will choose
H-score ≤10 as mesothelin-negative and H-score >10
as mesothelin-positive [18]. The survival data will be
extracted from the tables or texts of eligible articles
or estimated from Kaplan-Meier curves where it is
applicable [19]. If we encounter any missing or unclear-
ness of above information, study authors will be contacted
for additional details.
Quality assessment of included studies
The Newcastle-Ottawa Assessment Scale (NOS) [18] will
be employed by two independent reviewers (MW and
AL) to assess the methodological quality of all eligible
trials. The adapted version of the NOS will be used to
meet the specific needs of this systematic review [20].
Included studies will be assessed on three broad per-
spectives: the selection of the study groups, the compar-
ability of the groups, and the ascertainment of either the
exposure or outcome of interest for case-control or co-
hort studies, respectively [20]. Reviewers will classify the
risk of biases in the studies on a scale from 0 to 3, where
0 indicates a high risk of bias and 3 indicates low risk.
The adapted version of the NOS includes seven ques-
tions spread across four domains of evaluation: methods
for selecting study participants (selection bias), methods
to control for confounding (performance bias), statistical
methods (detection bias), and methods for measuring
exposure and outcome variables (information bias).
These scales will be used to measure the risk of bias on
a per study basis or categorized by domain to develop a
general conclusion about the sources of bias in the
studies included in this review (see Additional file 6)
[21]. Reviewers will resolve disagreements by discus-
sion, and one arbitrator will adjudicate unresolved
disputes (LM or LT).
Data synthesis and statistical analysis
The statistical reporting will be performed according to
the guidelines proposed by the MOOSE group [22]. De-
scriptive statistics will be used to describe the character-
istics of all eligible studies. Data will be presented as
mean (standard deviation) or median (first quartile, third
quartile) for both continuous variables and frequencies
(percent) for categorical variables. If there are a suffi-
cient number of studies (at least three) suitable for pool-
ing, we will perform meta-analyses of the studies to
obtain a pooled estimate of the association between the
expression levels of mesothelin and the survival of
TNBC expressed as odds ratio (at similar follow-up
points) or hazard ratio with 95 % confidence intervals
(CIs). This analysis will be conducted using STATA.
When heterogeneity is present, a random effect model
(Der Simonian and Laird method) will be applied, while
the fixed effect model will be used in the absence of
between-study heterogeneity (P > 0.10 or I2 < 50 %) [23].
We will consider the clinical heterogeneity of included
studies based on outcome measurements, follow-up
length, and methodological heterogeneity due to study
design (prospective versus retrospective).
We will synthesize data within these clinically relevant
subgroups. Between-study heterogeneity will be mea-
sured using the Cochrane’s Q test and Higgins I2 statistic
(P value of <0.10 or I2 > 50 % will be considered as statisti-
cally significant heterogeneity). If there is a large number
studies, we will use meta-regression or subgroup analyses
to explain the heterogeneity by lymph node metastasis,
pathological stage, and adjuvant chemotherapy.
Dealing with missing participant data, sensitivity analyses,
and publication bias
For missing data, we will contact study authors for clarifi-
cation and to attempt to retrieve any missing information.
We will conduct a complete case analysis (excluding those
with missing data) as the primary analysis [24], and a sen-
sitivity analysis will be performed to determine the articles
with more than 25 % missing data which influence the
overall result. If feasible, we will also perform a sensitivity
analysis by excluding trials with a high risk of bias to test
the robustness of our results.
If the number of eligible studies is too small (<10),
publication bias will not be assessed. If there are 10 or
more eligible studies, publication bias will be examined
for each meta-analysis by visually examining asymmetry
of funnel plots and testing for asymmetry at the 10 %
level, using Egger’s test for hazard ratios and Peters’ test
for odds ratios [25].
Discussion
The lack of expression of conventional prognostic markers
(estrogen, progesterone, and Her2 receptors) in TNBC
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denies those patients the benefit of targeted therapy against
these receptors. The search for a molecular therapeutic tar-
get for TNBC is ongoing. Mesothelin is identified as a bio-
marker for TNBC because some authors have identified its
overexpression in TNBC and limited expression in the
common luminal breast tumor subtype and normal tissues
[6]. A better understanding of the expression frequency
and prognostic value of mesothelin in TNBC will be essen-
tial to identify a novel therapeutic target with the goal of
improving health outcomes of patients with TNBC.
This proposed review will serve several purposes. First,
we hope to identify the expression level of mesothelin in
TNBC. Second, we will document survival rates linked
to the levels of mesothelin in TNBC. Our results will in-
form disease prognosis and highlight better therapeutic
and diagnostic timing strategies. There are ongoing in-
vestigations of agents that target mesothelin-expressing
tumors. Even if we find mesothelin has little prognostic
value in patients with TNBC, it may still be a promising
target for novel drug therapies in other cancers. Finally,
we hope the results of this review will encourage future
research in identifying mesothelin as a novel target for
improving the outcomes for patients with TNBC.
Our systematic review will be conducted according to
recommended standards including explicit eligibility cri-
teria, duplicate independent assessment of eligibility, and
a comprehensive search. We will use the NOS approach
to assessing methodological quality including duplicate
independent assessment of the validity of the individual
studies. Our results are only likely to be restricted by
limitations in the primary studies. To our knowledge,
this review will be the first systematic review about the
association between the expression levels of mesothelin
and clinical outcomes in patients with TNBC.
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